Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: A phase II study

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 809-815

  Bremer, Karl ^a  

^a Augusta Kranken Anstalt   (Germany)

Author keywords

Advanced low grade B cell non Hodgkin's lymphoma; Phase II study; Pre treated; Rituximab; Weekly infusions

Indexed keywords

RITUXIMAB;

ADULT; AGED; ALLERGIC DISEASE; ARTICLE; B CELL LYMPHOMA; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERANCE; DYSPNEA; EPIDERMIS; FEMALE; FEVER; HUMAN; HYPOTENSION; MALE; MEDICAL ASSESSMENT; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; REMISSION; RESPONSE TIME; SENSORY SYSTEM; SWEATING; VOMITING;

EID: 1542405230     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200311000-00006     Document Type: Article

References (39)

1. Reed JC, Kitada S, Kim Y, Byrd J. Modulating apoptosis pathways in low-grade B cell malignancies using biological response modifiers. Semin Oncol 2002; 29(1 suppl 2):10-24.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780-2795.
3. Vose JM. Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol 1998; 25:483-491.
4. Gutierrez-Delgado F, Golden J, Maloney DG, Holmberg L, Hooper H, Storb R, et al. High-dose chemotherapy (HDC) and autologous stem cell transplantation (AST) for non-Hodgkin's lymphoma. Five-year follow up. Proc Am Soc Clin Oncol 2000; 19:14a (abstr 46).
5. Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1998; 25:503-517.
6. Toze CL, Shepherd JD, Connors JM, Voss NJ, Gascoyne RD, Hogge DE, et al. Allografting for indolent lymphoid neoplasms. Ann Oncol 2000; 11 (suppl 1):59-61.
7. Kipps TJ. Advances in classification and therapy of indolent B cell malignancies. Semin Oncol 2002; 29(1 suppl 2):98-104.
8. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26(5 suppl. 14):66-73.
9. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29(1 suppl 2):2-9.
10. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266-3274.
11. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
12. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79:493-500.
13. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-324.
14. Ghielmini M, Hsu Schmitz SF, Cogliatti SB, Pichert G, Fey M, Betticher D, et al. Maintenance treatment with 2-monthly rituximab after standard weekly x 4 rituximab induction significantly improves event-free survival in patients with follicular lymphoma. Ann Oncol 2002; 13(suppl 2): 38 (abstr 112).
15. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655-661.
16. Stansfeld AG, Diebold J, Kapanci Y, Kelenyi G, Lennart K, Mioduszewska O, et al. Updated Kiel classification for lymphomas. Lancet 1998; 1:292-293.
17. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
18. Cancer Therapy Evaluation Program. Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents. Bethesda, MD: CTEP, National Cancer Institute; 1993.
19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17:1244-1253.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
21. Peto R, Peto J. Asymptomatically efficient rank invariation test procedures (with discussion). J R Stat Soc Ass 1972; 135:185-206.
22. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, Link B, Maloney DG, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17:1851-1857.
23. Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13:928-943.
24. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-3143.
25. Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97:101-106.
26. Hainsworth JD, Litchy S, Burris III HA, Scullin DC, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267.
27. Molica S, Levato D, Dattilo A, Mannella A. Clinico-prognostic relevance of quantitative immunophenotyping in B cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur J Haematol 1998; 60:47-52.
28. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al. Rituximab therapy of patients with B cell chronic lymphocytic leukemia. Blood 2001; 98:1326-1331.
29. Conconi A, Thieblemont C, Martinelli F, Ferreri AJ, Devizzi L, Peccatori F, et al. IELSG phase II study of rituximab in MALT-lymphomas. Ann Oncol 2002; 13(suppl 2):81(abstr 272).
30. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001; 12:725-729.
31. Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia J Cancer Res Clin Oncol 2001; 127:48-54.
32. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128:603-609.
33. Bergmann L. Purine analogues in the therapy of chronic leukemia and indolent lymphomas. Onkologie 1997; 20:278-286.
34. Tulpule A, Schiller G, Harvey-Buchanan LA, Lee M, Espina BM, Khan AU, et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer 1998; 83:2370-2376.
35. Tondini C, Balzarotti M, Rampinelli I, Valagussa P, Luoni M, De Paoli A, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 2000; 11:231-233.
36. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
37. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002; 29(1 suppl 2):36-40.
38. Hainsworth JD, Buris III HA, Yardley DA, Litchy S, Morrissey L, Grimaldi M, et al. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma (NHL): a Minnie Pearl Cancer Research Network phase III trial. Proc Am Soc Clin Oncol 2002; 21 (abstr 1070).
39. Rummel MJ, Kim SZ, Chow KU, Weidmann E, Hoelzer D, Mitrou PS. Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of indolent and mantle-cell lymphomas pre-treated with purine analogues. Ann Oncol 2002; 13(suppl 2):58 (abstr 187).